Highlight
- A randomized clinical trial directly compared amiloride and spironolactone in resistant hypertension for the first time.
- Amiloride was shown to be noninferior to spironolactone in reducing home-measured systolic blood pressure after 12 weeks.
- The rates of achieving target systolic blood pressure (<130 mm Hg) were comparable between amiloride and spironolactone groups.
- Amiloride had a favorable safety profile with no gynecomastia cases and only one hyperkalemia-related discontinuation.
Study Background and Disease Burden
